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O B J E C T I V E S This study sought to test whether aortic valve calcium (AVC) is independently
associated with coronary and cardiovascular events in a primary-prevention population.
B A C KG ROUND Aortic sclerosis is associated with increased cardiovascular morbidity and mortal-
ity among the elderly, but the mechanisms underlying this association remain controversial. Also, it is
unknown whether this association extends to younger individuals.
METHOD S We performed a prospective analysis of 6,685 participants in MESA (Multi-Ethnic Study
of Atherosclerosis). All subjects, ages 45 to 84 years and free of clinical cardiovascular disease at baseline,
underwent computed tomography for AVC and coronary artery calcium scoring. The primary, pre-
speciﬁed combined endpoint of cardiovascular events included myocardial infarctions, fatal and nonfatal
strokes, resuscitated cardiac arrest, and cardiovascular death, whereas a secondary combined endpoint
of coronary events excluded strokes. The association between AVC and clinical events was assessed
using Cox proportional hazards regression with incremental adjustments for demographics, cardiovas-
cular risk factors, inﬂammatory biomarkers, and subclinical coronary atherosclerosis.
R E S U L T S Over a median follow-up of 5.8 years (interquartile range: 5.6 to 5.9 years), adjusting for
demographics and cardiovascular risk factors, subjects with AVC (n  894, 13.4%) had higher risks of
cardiovascular (hazard ratio [HR]: 1.50; 95% conﬁdence interval [CI]: 1.10 to 2.03) and coronary (HR: 1.72; 95%
CI: 1.19 to 2.49) events compared with those without AVC. Adjustments for inﬂammatory biomarkers did not
alter these associations, but adjustment for coronary artery calcium substantially attenuated both cardiovas-
cular (HR: 1.32; 95% CI: 0.98 to 1.78) and coronary (HR: 1.41; 95% CI: 0.98 to 2.02) event risk. AVC remained
predictive of cardiovascular mortality even after full adjustment (HR: 2.51; 95% CI: 1.22 to 5.21).
CONC L U S I O N S In this MESA cohort, free of clinical cardiovascular disease, AVC predicts cardio-
vascular and coronary event risk independent of traditional risk factors and inﬂammatory biomarkers,
likely due to the strong correlation between AVC and subclinical atherosclerosis. The association of AVC
with excess cardiovascular mortality beyond coronary atherosclerosis risk merits further investigation.
(Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487) (J Am Coll Cardiol Img 2012;5:619–25)
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620alcific aortic valve disease is common in
older adults, with an estimated prevalence
of 25% in individuals older than 65 years
of age (1). Thought previously to be a
egenerative disorder, the disease is now recognized
o be an actively regulated biological process sharing
any epidemiological (1–4) and histopathological
5) similarities to coronary atherosclerosis.
In older adults without known cardiovascular
isease, aortic sclerosis (the presence of valve cal-
ium without hemodynamic obstruction) is associ-
ted with a 50% increase in risk of cardiovascular
vents (6). Hypothesized mechanisms underlying this
ssociation include inflammation, subclinical athero-
clerosis, and other shared biological mechanisms.
To determine whether the presence of aortic valve
alcium (AVC), detected on computed tomography
CT) scans, predicts cardiovascular events in a younger
ohort and to identify mechanisms underlying this asso-
iation, we performed a prospective analysis in MESA
Multi-Ethnic Study of Atherosclerosis).
M E T H O D S
Study population: MESA is a National
Heart, Lung, and Blood Institute–
sponsored, population-based investigation
of subclinical cardiovascular disease and its
progression (7). In this study, a total of
6,814 individuals, ages 45 to 84 years,
were recruited from 6 U.S. communities
(Baltimore City and County, Maryland;
Chicago, Illinois; Forsyth County, North
Carolina; Los Angeles County, California; New
York, New York; and St. Paul, Minnesota) between
July 2000 and August 2002. Pre-specified recruit-
ment plans targeted 4 ethnic groups (white, black,
Hispanic, and Chinese). Participants were excluded
if they had physician-diagnosed cardiovascular dis-
ease before enrollment, including angina, myocar-
dial infarction (MI), heart failure, stroke or tran-
sient ischemic attack, resuscitated cardiac arrest, or
a cardiovascular intervention (e.g., coronary artery
bypass graft, angioplasty, valve replacement, pace-
maker/defibrillator placement). Subjects with sub-
clinical aortic valve disease (e.g., bicuspid valves)
were thus eligible for participation. The institu-
tional review board at each participating institution
approved MESA, and each participant provided
informed written consent before enrollment.
Demographic and covariate data. The comprehen-
sive baseline MESA examination included a clinic
m
yvisit, serum analyses, and a CT scan of the chest and aheart. Information regarding the participants’ de-
mographic data and medical history, including
medication use, was obtained by questionnaire.
Ethnicity was self-reported. Baseline testing for and
definitions of cardiovascular risk factors were de-
scribed previously (8). Serum samples were obtained
after a 12-h fast and analyzed in a central laboratory
(University of Vermont, Burlington, Vermont).
C-reactive protein (CRP) concentrations were ana-
lyzed using the BNII high-sensitivity nephelometer
(Dade Behring, Inc., Deerfield, Illinois). Diabetes and
impaired fasting glucose were defined according to the
2003 American Diabetes Association fasting criteria
algorithm or a history of diabetes treatment. Renal
function was estimated using the Modification of Diet
in Renal Disease equation.
CT analysis. All MESA participants underwent
baseline CT scans that were analyzed for both
coronary artery calcium (CAC) and AVC. Three
institutions used an electron beam tomography
Imatron C150 scanner (GE Medical Systems, Mil-
waukee, Wisconsin), whereas 3 institutions used
4-slice multidetector CT scanners. Spatial resolu-
tion was 1.38 mm3 for electron beam tomography
(0.68  0.68  3.00 mm) and 1.15 mm3 for
ultidetector CT (0.68  0.68  2.50 mm). Full
etails concerning the equipment, scanning meth-
ds, and quality control, including image calibra-
ion, phantom adjustment, and interscanner repro-
ucibility, were reported previously (9,10).
All scans were sent to a central MESA CT
eading center (Harbor-UCLA Research and Edu-
ation Institute, Los Angeles, California). Calcium
trongly attenuates x-rays, appears bright on CT
cans, and is readily differentiated from surrounding
issue. The methods for CAC scoring in MESA
ere described previously (11). Consistent with
ccepted methodology (10,12–14), lesions were
lassified as AVC if they resided within the aortic
alve leaflets, exclusive of the aortic annulus or coro-
ary arteries, and contained 3 contiguous pixels of
130 Hounsfield units of brightness. Using Agatston
ethodology (15), single-lesion calcium contents
ere summed to give a total AVC score. If no lesions
eached threshold, the AVC score was 0.
Outcomes assessment. MESA participants were fol-
owed prospectively from the time of enrollment.
o capture unreported events, telephone interviews
ere conducted every 9 to 12 months. More than
9% of self-reported hospitalizations and 97% of
ardiovascular outpatient diagnoses and procedures
ere investigated through medical record review,A B B R E V I A T I O N S
A N D A C R O N YM S
AVC aortic valve calcium
AC coronary artery calciu
I confidence interval
CRP C-reactive protein
T computed tomograph
HR hazard rationd incident aortic valve disease and valve replace-
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621ments were identified by ICD-9 diagnosis and
procedure codes. Death investigations included ex-
amination of death certificates and next-of-kin
interviews. Each event was adjudicated by 2 physi-
cians, with committee review of disagreements.
Deaths potentially due to cardiovascular causes were
adjudicated by the full committee.
The combined endpoints of major coronary
events (MI, resuscitated cardiac arrest, and cardio-
vascular death) and major cardiovascular events
(coronary events plus nonfatal or fatal stroke) were
pre-specified by MESA. Definite or probable MIs
were defined by symptoms, electrocardiographic
findings, and abnormal cardiac biomarker levels
Table 1. Baseline Demographics and Risk Factors According to
All Subjects
(N  6,685)
Age, yrs 62 10
Male 3,157 (47)
Race/ethnicity
White 2,583 (39)
Chinese 795 (12)
Black 1,832 (27)
Hispanic 1,475 (22)
Body mass index, kg/m2 28.3 5.5
Hypertension 2,997 (45)
Medical therapy 2,486 (37)
Blood pressure, mm Hg
Systolic 127 22
Diastolic 72 10
Diabetes status
Normal 4,922 (74)
Impaired fasting glucose 924 (14)
Diabetes 839 (13)
Smoking status
Never 3,362 (50)
Former 2,455 (37)
Current 868 (13)
Pack-years smoking 16 (6–32)
Family history of MI 2,680 (40)
Cholesterol, mg/dl
Total 194 36
Low density 117 31
High density 51 15
Triglycerides† 111 (78–161)
Cholesterol/HDL ratio 4.1 (1.2)
Lipid-lowering medications 1,088 (16)
CRP, mg/dl 1.91 (0.84–4.2
Estimated GFR, mlmin1 (1.73 m2)1 81 (18)
CAC 3,339 (50)
Values are mean  SD, n (%), or median (interquartile range). SI conversion fact
triglyceride concentrations to mmol/l, multiply by 0.01129; to convert creatinin
AVC  aortic valve calcium; CAC  coronary artery calcium; CFP  C-react
MI  myocardial infarction.(2 times upper limits of normal). Strokes were
defined as neurological deficits lasting 24 h or
lesions on brain imaging consistent with a localized
ischemic or hemorrhagic event.
Data analyses. MESA participants were categorized
ccording to the presence (AVC score 0) or
bsence (AVC score  0) of AVC on baseline
xamination. Differences in baseline demographic
eatures were compared using chi-square test of pro-
ortions or the Student t test comparison of means
here appropriate. Event rates were described and
isplayed using Kaplan-Meier cumulative events
ethods. The risks associated with the presence of
VC, adjusted for baseline demographic features,
Presence of AVC
No AVC
(n  5,791)
AVC
(n  894) p Value
61 10 70 8 0.0001
2,621 (45) 536 (60) 0.0001
0.0001
2,181 (38) 402 (45)
729 (13) 66 (7)
1,605 (28) 227 (25)
1,276 (22) 199 (22)
28.3 5.5 28.5 5.0 0.26
2,421 (42) 576 (64) 0.0001
1,991 (34) 495 (55) 0.0001
125 21 135 22 0.0001
72 10 72 10 0.52
0.0001
4,350 (75) 572 (64)
783 (14) 141 (16)
648 (11) 181 (20)
0.0001
2,972 (51) 390 (44)
2,044 (35) 411 (46)
775 (13) 93 (10)
15 (6–31) 20 (7–44) 0.0001
2,277 (39) 403 (45) 0.0001
194 35 195 38 0.37
117 31 119 31 0.11
51 15 49 14 0.0001
110 (77–159) 120 (83–172) 0.0006
4.0 (1.2) 4.2 (1.2) 0.0001
856 (15) 232 (26) 0.0001
1.89 (0.82–4.26) 2.05 (0.95–4.09) 0.04
82 (18) 76 (19) 0.0001
2,609 (45) 730 (82) 0.0001
to convert cholesterol concentrations to mmol/l, multiply by 0.0259; to convert
mol/l, multiply by 88.4.
rotein; GFR  glomerular ﬁltration rate; HDL  high-density lipoprotein;the
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622were estimated using Cox proportional hazards re-
gression. Schoenfeld residual and log-minus-log sur-
vival plots were used to confirm the proportional
hazards assumptions of these models.
Incremental model building was performed to
demonstrate the impact of baseline factors on overall
risk. Model 1 included adjustments for age, sex, and
race. Model 2 additionally adjusted for body size,
cardiovascular risk factors, and renal function. Model
3 additionally included adjustment for CRP, which
was log-transformed before inclusion due to its
skewed distribution. Exploratory models adding fi-
brinogen and interleukin-6 were also performed, but
did not substantively alter the results.
Model 4 included adjustment for baseline
CAC score, modeled as a log-transformed vari-
able using the sum of the CAC score plus 1 (i.e.,
log[CAC  1]) to permit inclusion of subjects
with CAC scores of 0. Exploratory analyses using
alternative CAC transformations were per-
formed, including Greenland categories (0, 1 to
100, 100 to 300, and 300) (16) and a square
root transformation, but these did not substan-
tively alter the analytical results.
All statistical analyses were performed with Stata
version 11.0 for Windows (StataCorp, College
Station, Texas). Statistical significance was defined
as p  0.05, and hazard ratios (HRs) are reported
with 95% confidence intervals (CIs).
R E S U L T S
Study subjects. Of the 6,814 participants initially re-
cruited into MESA, 6,685 were included in these anal-
yses. Participants were excluded because of cardiovascular
events before enrollment (n 5, 0.1%), lost to follow-up
(n  33, 0.5%), no baseline AVC scoring (n  1,
0.01%), and missing covariate data (n 90, 1.3%). Two
excluded subjects had strokes during follow-up, 1 each
with and without AVC at baseline.
The baseline characteristics of the study cohort are
shown in Table 1. AVC was observed in 13% of the
cohort at baseline, with a median Agatston score of 58
(interquartile range: 20 to 149). Subjects with AVC
were older and more likely to be male and had worse
overall cardiovascular risk factor profiles. Additionally,
subjects with AVC were more likely to have CAC and
to have higher CAC scores (Fig. 1).
Subjects were followed for a median of 5.8 years
(interquartile range: 5.6 to 5.9 years), with a max-
imum follow-up of 7.1 years. During this period,
there were 40 cases of incident aortic valve disease rand 22 aortic valve replacements, as well as 160
coronary and 255 cardiovascular events.
Risk of coronary and cardiovascular events. Figure 2
depicts the unadjusted Kaplan-Meier cumulative
event curves for major coronary and cardiovascular
events, respectively. After adjusting for age, race, and
sex (Table 2, model 1), the presence of AVC was a
strong predictor of both cardiovascular and coronary
events. Although these risks were attenuated after
adjusting for known atherosclerotic risk factors (Table 2,
model 2), AVC remained predictive of both cardio-
vascular (HR: 1.50; 95% CI: 1.10 to 2.04) and
coronary (HR: 1.72; 95% CI: 1.19 to 2.49) events.
The inclusion of CRP in the model (Table 2,
model 3) did not alter these findings. However, in the
fully adjusted model that included adjustments for
both CRP and CAC scores (Table 2, model 4), AVC
demonstrated a borderline association with cardiovas-
cular (HRL 1.32; 95% CI: 0.98 to 1.78) and coronary
(HR: 1.41; 95% CI: 0.98 to 2.02) events. Addition-
ally, there was no significant trend in risk across AVC
tertiles for either outcome (HR: 1.17, p  0.32 and
HR  1.09, p  0.66, respectively).
Risk by event type. In fully adjusted models incor-
orating demographics, cardiovascular risk factors,
nflammatory biomarkers, and CAC scores, the
resence of AVC was not associated with increased
isk of MI or stroke (Table 3), but was associated
ith a 2.76-fold (95% CI: 1.44 to 5.30) higher risk
f cardiovascular death or resuscitated cardiac ar-
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Figure 1. Distribution of CAC Scores, Stratiﬁed by
Presence of AVC
The prevalence of coronary artery calcium (CAC) categories (CAC
score  0, 100, 100 to 300, and 300) among MESA partici-
pants with (n  894) and without (n  5,791) aortic valve cal-
cium (AVC) at baseline. Participants with baseline AVC had a
higher prevalence of CAC (87.1% vs. 45.1%, p  0.0001) com-
pared with those without AVC, with skewing of the distribution
of CAC scores toward more severe calciﬁcation.est. These results were unaltered (HR: 2.72; 95%
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623CI: 1.37 to 5.40; p  0.004) when subjects with
clinical progression (incident clinical valve disease
or valve replacement, n  54) or higher baseline
calcium (AVC score 100, n  293) were ex-
cluded. Increasing tertiles of AVC were observed to
have increased event rates (Fig. 3). Compared with
those without AVC, those with AVC scores of 1.9
to 29.2, 29.4 to 107, and 107.5 to 7,672 had a
2.18-fold (95% CI: 0.93 to 5.12), 3.10-fold (95%
CI: 1.31 to 7.37), and 3.02-fold (95% CI: 1.22 to
7.43) higher risk of cardiovascular death, respec-
tively, after full adjustment.
Risk by race/ethnicity. After adjustment for demo-
raphics, cardiovascular risk factors, inflammation,
nd CAC score, there were no significant differ-
nces by race/ethnicity in the association of AVC
ith either cardiovascular (p interaction  0.12) or
oronary (p interaction  0.13) events.
D I S C U S S I O N
Calcific aortic valve disease begins in midlife as a
clinically latent but progressive disorder and often is
detected incidentally. Yet even in this latent, pre-
obstructive phase, the presence of aortic valve cal-
cium appears to be a marker of increased cardiovas-
cular risk. Previous results from the CHS
(Cardiovascular Health Study) showed that, among
adults older than 65 years of age, echocardiographi-
cally detected aortic sclerosis was associated with a
50% increased risk of cardiovascular mortality (6).
In that study, aortic sclerosis also was associated
with a 42% increase in risk of MI. However, these
analyses were unable to control for the presence of
subclinical atherosclerosis and systemic inflamma-
tion, plausible mediators of these associations.
Our results extend these previous findings to a
younger, healthier, and multiethnic population and
offer a partial explanation for the observed association
between aortic sclerosis and coronary events. Among
participants age 45 to 84 years and free of cardiovas-
cular disease at baseline and after adjustment for
demographics and cardiovascular risk profiles, the
presence of AVC on CT was associated with a
significant, 50% higher risk of cardiovascular events
and a 72% higher risk of coronary events. Notably,
these results are similar in magnitude to echocardio-
graphically detected aortic sclerosis in CHS. These
risk estimates were unaltered by adjustment for in-
flammatory biomarkers, suggesting that systemic in-
flammation did not account for these associations.
Conversely, the risk estimates were attenuated sub-
stantially after adjusting for the severity of subclinicalatherosclerosis, as estimated by CAC scores. CAC has
been strongly and independently associated with car-
diovascular events across a range of age, ethnic, and
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Figure 2. Kaplan-Meier Event Curves for Primary and Secondary
Outcomes
Unadjusted Kaplan-Meier cumulative event curves depicting the ca
cular (A) and coronary (B) events rates among participants with (re
without (green) aortic valve calcium (AVC) at baseline. At the medi
years of follow-up, participants with AVC had higher unadjusted rat
both cardiovascular (3.2% vs. 10.2%, p  0.0001) and coronary (1.9
6.9%, p  0.0001) events compared with participants without AVC.
Table 2. Incrementally Adjusted Risks of Cardiovascular Events
Associated With the Presence of Aortic Valve Calciﬁcation
Major Cardiovascular
Event
(n  255)
Major Coronary
Event
(n  160)
HR (95% CI)
p
Value HR (95% CI)
p
Value
Model 1 1.82 (1.37–2.42) 0.001 2.07 (1.45–2.95) 0.001
Model 2 1.50 (1.10–2.04) 0.009 1.72 (1.19–2.49) 0.004
Model 3 1.50 (1.10–2.03) 0.01 1.72 (1.19–2.49) 0.004
Model 4 1.32 (0.98–1.78) 0.07 1.41 (0.98–2.02) 0.07
Model 1 included adjustments for age, sex, and race. Model 2 included all
variables in model 1 plus adjustments for body mass index, systolic and
diastolic blood pressure, diabetes status, use of antihypertensive therapy,
smoking status, family history of heart attack, total cholesterol, high-density
lipoprotein cholesterol, triglycerides, use of cholesterol-lowering medications,
and renal function. Model 3 included all variables in model 2 plus adjustment
for log(C-reactive protein). Model 4 included all variables in model 3 plus
adjustment for log(coronary artery calcium score  1).AVC
 AVC
6
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624risk profiles (8,16–18). We found a strong association
between the presence of AVC and both the prevalence
and severity of CAC in MESA (Fig. 1), and after
adjusting for CAC, the observed risk of MI ap-
proached unity. These findings suggest that CAC
scores are an effective marker of coronary event risk
and that a substantial portion of the increased risk of
cardiovascular morbidity seen with AVC is due to
coexistent subclinical atherosclerosis.
To test whether AVC was associated with clinical
events, we performed extensive adjustments beyond
the standard Framingham risk factors, including ad-
justments for body mass index, diabetes, impaired
Years to Event
5791 5753 5668 5580 5480 5338 923
298 297 287 277 272 264 48
297 295 288 284 275 256 40
299 290 278 268 258 242 22
No AVC
Tertile 2 (29-107)
Tertile 1 (1-29)
Tertile 3 (108-7672))
108-7672
29-107
1-29
No AVC
0
0
0
0
0
0
0 1 2 3 4 5 6
Kaplan-Meier Event Curves for CV Mortality
Kaplan-Meier cumulative event curves for the combined end-
rdiovascular (CV) death or resuscitated cardiac arrest (RCA), strati-
tiles of baseline aortic valve calcium (AVC) score. At the median
f follow-up, the unadjusted event rate for participants without
VC was 0.5% compared with event rates of 2.1% (tertile 1), 3.2%
and 3.7% (tertile 3) for those with increasing severity of baseline
full adjustment for age, sex, cardiovascular risk factors, renal func-
oronary artery calcium scores, there remained a 1.48-fold (95%
interval: 1.14 to 1.95; p  0.004) increase in risk of CV death or
Table 3. Number of Pre-Speciﬁed Events by Event Type, Stratiﬁ
Total
(N  6,685)
No A
(n  5
Coronary, n (%)
MI 126 (1.9) 87 (1
Resuscitated cardiac arrest 17 (0.3) 8 (0
Cardiovascular death† 36 (0.5) 18 (0
Cardiovascular, n (%)
Any stroke 103 (1.5) 71 (1
Fatal stroke 13 (0.2) 10 (0
Events may not add up due to synchronous events (e.g., MI resulting in cardiov
age, race, sex, body mass index, systolic and diastolic blood pressure, use of ant
cholesterol, high-density lipoprotein cholesterol, triglycerides, use of lipid-lowe
scores. †Cardiovascular deaths excluding strokes.
Abbreviations as in Tables 1 and 2.rtile increase in AVC score.fasting glucose, pack-years of smoking, family history
of MI, use of lipid-lowering therapy, and renal func-
tion. Thus, our findings do not preclude the possibility
that AVC adds to Framingham risk prediction. Among
5,877 nondiabetic subjects in MESA, AVC remained
strongly associated with coronary events after adjustment
for Framingham risk factors alone (HR: 1.85; 95% CI:
1.33 to 2.59) and Framingham risk factors plus CAC
(HR: 1.42; 95% CI: 1.02 to 1.98). Whether AVC
improves risk categorization beyond Framingham risk
calculations requires more detailed analyses beyond the
scope of the present investigation.
In pre-specified exploratory analyses, AVC re-
mained an independent predictor of cardiovascular
mortality after adjustment for risk factors and CAC
severity. Given the low event rate, this finding must be
interpreted with caution. Nonetheless, this finding is
intriguing because this excess mortality may be unre-
lated to progressive valve disease. Participants with
substantial calcium progression likely would have de-
veloped symptoms and undergone valve replacement,
whereas death from asymptomatic aortic stenosis is
relatively uncommon (19), even in very severe aortic
stenosis (20). Previous studies suggest that aortic
stenosis is uncommon with AVC scores 150
13,14), and exclusion of those with known progres-
ion and those with AVC scores 100 did not alter
he risk association. The mechanisms underlying this
bserved association remain unexplained, and further
nvestigations are warranted.
Study limitations. First, AVC was not a pre-
specified variable in MESA, and CT scans obtained
for the purpose of CAC scoring were analyzed
retrospectively. Second, only baseline risk factor
profiles were included as covariates, and changes in
profiles were not evaluated. Third, the rate of
y the Presence or Absence of AVC at Baseline
)
AVC
(n  894)
HR (95% CI)
Age, Race, Sex
Fully
Adjusted*
39 (4.3) 1.67 (1.11–2.52) 1.11 (0.73–1.68)
9 (1.0) 5.94 (2.05–17.2) 5.37 (1.43–20.1)
18 (2.2) 3.66 (1.79–7.48) 2.51 (1.22–5.21)
32 (3.6) 1.75 (1.11–2.74) 1.38 (0.84–2.27)
3 (0.4) 0.74 (0.19–2.82) 0.59 (0.14–2.51)
ar death would be classiﬁed as a single coronary event). *HRs are adjusted for
rtensive medication, diabetes status, smoking status, pack-years smoked, total
medications, renal function, C-reactive protein, and log of coronary calciumCV
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625the power to detect risk associations. Finally, par-
ticipants and their physicians were informed of high
CAC scores, knowledge that may have prompted
therapy to reduce cardiovascular risk; however, such
treatment would likely bias results toward the null.
C O N C L U S I O N S
In a multiethnic cohort without clinical cardiovascular
disease at baseline, AVC was associated with risks of
coronary and cardiovascular events beyond those pre-
dicted by traditional risk factors. These risk associa-
tions were attenuated after adjustment for CAC but
not for inflammatory markers, suggesting that AVC
partly serves as a marker of subclinical atherosclerosis
severity. Whether AVC adds to cardiovascular riskcoronary events in four racial or ethnic
1
1
1
1
1
110:356–62.merits additional investigation. Finally, through
mechanisms yet to be elucidated, the association of
AVC with excess cardiovascular mortality remained,
even after adjustment for risk factors, inflammation,
and subclinical atherosclerosis.
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